The edition · Ophthalmology
SGLT2 inhibitors are associated with slower diabetic retinopathy progression
A meta-analysis of 1.8 million patients links SGLT2 inhibitors to less retinopathy and macular oedema progression than other glucose-lowering drugs, adding a dexamethasone implant to aflibercept clears oedema faster without improving vision, and a glaucoma drop is recalled for a container that will not deliver a drop.
The edition in brief
The glucose-lowering drug a physician chooses may affect the eye, not only the kidney and heart. A meta-analysis of 16 studies and 1,785,409 patients found SGLT2 inhibitors associated with a 23% lower relative risk of diabetic retinopathy progression against all other glucose-lowering agents, and 25% lower for macular oedema. In a cohort with 20% baseline retinopathy that is about a 4 percentage point absolute difference. The advantage was largest against sulfonylureas and least clear against GLP-1 receptor agonists. This is observational and is a reason to raise the eye in the prescribing conversation, not to change a regimen on its own. The COED trial added a dexamethasone implant to aflibercept for diabetic macular oedema. Central subfield thickness and visual acuity at 48 weeks were no different from aflibercept alone. Oedema resolved a median 12 weeks sooner and fewer injections were needed, but three eyes developed worsening cataract and two needed pressure-lowering treatment. Faster, not better. On safety, retinal detachment after intravitreal anti-VEGF is rare — about 1 in 8,675 injections, or 1 in 1,250 eyes over a treatment course. And the FDA has a Class II recall on dorzolamide-timolol from Micro Labs for broken cap spikes and undeliverable drops, which matters directly for glaucoma patients dispensed that product.
SGLT2 inhibitors track with slower retinopathy progression than the alternatives
In a patient with established diabetic retinopathy, raise the choice of glucose-lowering agent with the physician managing it — SGLT2 inhibitors track with slower progression than sulfonylureas in particular.
Adding a dexamethasone implant to aflibercept clears oedema faster, not better
Add a dexamethasone implant to aflibercept when injection burden or attendance is the problem, not when you want better vision — it resolves oedema faster at the cost of cataract and pressure.
Class II recall of dorzolamide-timolol for bottles that will not deliver a drop
If a patient on dorzolamide-timolol has an unexplained pressure rise, ask to see the bottle before recording non-adherence — an ongoing Class II recall names broken cap spikes and undeliverable drops.
Order the retinal screen for the whole list, not one patient at a time
Place diabetic retinopathy screening orders in bulk across the eligible list rather than one consultation at a time — it raised completion odds by 78%, from a baseline that was still under one in five.
Retinal detachment after an anti-VEGF injection is about 1 in 8,675 — per injection
Consent for anti-VEGF using the per-eye figure of about 1 in 1,250, not the per-injection 1 in 8,675 — and treat severe proliferative diabetic retinopathy as a separate, much higher-risk conversation.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free